Biodesix (NASDAQ:BDSX) Director Jack Schuler Purchases 82,465 Shares

Biodesix, Inc. (NASDAQ:BDSX) Director Jack Schuler acquired 82,465 shares of the business’s stock in a transaction that occurred on Thursday, January 22nd. The shares were acquired at an average cost of $10.96 per share, for a total transaction of $903,816.40. Following the completion of the acquisition, the director owned 1,463,210 shares of the company’s stock, valued at $16,036,781.60. This trade represents a 5.97% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Biodesix Stock Down 14.1%

Shares of NASDAQ BDSX opened at $10.09 on Tuesday. Biodesix, Inc. has a 12-month low of $3.44 and a 12-month high of $21.80. The stock’s fifty day simple moving average is $7.67 and its two-hundred day simple moving average is $7.69. The stock has a market capitalization of $80.32 million, a PE ratio of -1.81 and a beta of 0.60. The company has a current ratio of 1.84, a quick ratio of 1.84 and a debt-to-equity ratio of 41.11.

Biodesix (NASDAQ:BDSX) last issued its quarterly earnings data on Monday, November 3rd. The company reported ($1.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.60) by $0.44. Biodesix had a negative return on equity of 504.41% and a negative net margin of 49.31%.The firm had revenue of $21.77 million during the quarter, compared to analysts’ expectations of $20.98 million. As a group, analysts expect that Biodesix, Inc. will post -0.35 EPS for the current fiscal year.

Institutional Trading of Biodesix

Several large investors have recently bought and sold shares of the stock. XTX Topco Ltd raised its holdings in shares of Biodesix by 99.4% in the second quarter. XTX Topco Ltd now owns 205,647 shares of the company’s stock worth $58,000 after buying an additional 102,494 shares during the last quarter. Millennium Management LLC acquired a new position in shares of Biodesix in the 3rd quarter valued at $113,000. Oracle Investment Management Inc. purchased a new position in Biodesix in the 3rd quarter worth $113,000. Finally, Aberdeen Group plc purchased a new position in Biodesix in the 4th quarter worth $1,784,000. Hedge funds and other institutional investors own 20.96% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on BDSX. Weiss Ratings reiterated a “sell (e+)” rating on shares of Biodesix in a research note on Monday, December 22nd. Wall Street Zen raised Biodesix from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $32.50.

About Biodesix

Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.

The company’s flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.